News

Precigen Reports Q3 2024 Progress and Financial Insights

Precigen Reports Q3 2024 Progress and Financial Insights

Key Developments in Q3 2024

Precigen, Inc. (NASDAQ: PGEN) recently reported its financial results for the third quarter of 2024, along with critical business updates that highlight the company's strategic direction and innovative developments in gene and cell therapies.

Regulatory Progress and Clinical Updates

The company successfully completed a pre-BLA meeting with the FDA, achieving full alignment on the Biologics License Application (BLA) content, including pivotal chemistry, manufacturing, and controls (CMC) modules. This positions the company for a rolling BLA submission for PRGN-2012, an investigational therapy for recurrent respiratory papillomatosis (RRP) under the accelerated approval pathway.

Moreover, Precigen has initiated a confirmatory clinical trial for PRGN-2012, following FDA guidance, to commence prior to the BLA submission. The campaign for commercial and manufacturing readiness for PRGN-2012 is currently underway, aiming for a potential launch in 2025.

Strengthening Platforms for Future Growth

In addition to PRGN-2012, Precigen is gearing up for an end of Phase 1b meeting with the FDA in early 2025 to discuss PRGN-3006, a treatment for acute myeloid leukemia (AML). Data from preclinical studies on PRGN-3008, a next-generation UltraCAR-T therapy targeting CD19, was recently presented at a leading oncology conference, cementing its position as a competitive therapy for oncology and autoimmune diseases.

Helen Sabzevari, PhD, President and CEO of Precigen, highlighted the strategic reprioritization of resources to advance PRGN-2012 and emphasized continued innovations through their UltraCAR-T platform.

Financial Highlights of Q3 2024

During this quarter, Precigen reported an increase in selling, general, and administrative (SG&A) expenses by 7% compared to the previous year. This rise is mainly due to the heightened focus on advancing PRGN-2012 in preparation for its commercial launch. R&D costs saw a 2% decrease thanks to strategic resource allocation and streamlining operations.

The company closed a public offering of common stock with net proceeds of about $30.9 million, aiding its financial stability during this critical phase. However, net losses amounted to $24 million, compared to $19.8 million for the same period last year, attributed to investments in crucial therapies and workforce restructuring.

Pipeline and Future Directions

Precigen's ongoing work in the RRP field, along with its commitment to developing cutting-edge therapies like PRGN-2009 for HPV-associated cancers, showcases its dedication to harnessing innovative treatments to address pressing health challenges. The company remains focused on its confirmatory trials and is exploring partnerships that can enhance its capabilities while reducing financial burdens.

About Precigen

Precigen, Inc. (NASDAQ: PGEN) is a clinical-stage biopharmaceutical company dedicated to the development of innovative gene and cell therapies. With a focus on immuno-oncology, autoimmune disorders, and infectious diseases, the company aims to advance the next generation of targeted therapies that provide affordable biotherapeutics in a controlled manner. For more detailed information, potential partners and patients can visit Precigen's official website.

Frequently Asked Questions

What is the strategic focus of Precigen moving forward?

Precigen is concentrating on advancing therapies like PRGN-2012 for RRP and exploring partnerships to enhance its resource allocation during potential commercialization efforts.

What are PRGN-2012 and PRGN-3006?

PRGN-2012 is an investigational therapy for recurrent respiratory papillomatosis, while PRGN-3006 is a treatment targeting acute myeloid leukemia, both representing key advancements in Precigen's pipeline.

How did Precigen's financial performance compare year-on-year?

Precigen reported a net loss of $24 million in Q3 2024, compared to $19.8 million in Q3 2023, reflecting increased investment in R&D and workforce adjustments.

What recent data was presented for PRGN-3008?

Preclinical data for PRGN-3008, targeting CD19, indicated promising results that may position it as a best-in-class therapy, with potential applications in oncology and autoimmune diseases.

How significant is the FDA's involvement for Precigen?

The FDA's alignment on the BLA submissions and its ongoing guidance for clinical trials greatly supports Precigen's efforts to bring innovative therapies to market effectively.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 4

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 9

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 5

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
Timur Turlov Leads FIDE with Chess and Digital Focus

Updated Category News Views 5

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 4

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 4

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 6

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
Farm Aid 2026: A Resilient Tribute to Family Farmers

Updated Category News Views 4

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Accounts Receivable Management with Bectran's New Feature

Updated Category News Views 218

Revolutionizing Accounts Receivable Management Bectran, Inc., a leader in connected intelligence for credit and accounts receivable management, has launched an innovative new command center for Accounts Receivable (AR) management. This feature is designed to meet the growing demands of finance professionals, providing them with a streamlined tool for managing receivables...

Continue Reading
Kaspi.kz Stock Investigation Unveils Serious Allegations

Updated Category News Views 75

Key Concerns Surrounding Kaspi.kz Stock Performance Recent events have sparked significant interest and concern among investors in Joint Stock Company Kaspi.kz (NASDAQ: KSPI). The stock has faced notable declines, drawing attention to potential underlying issues within the company. Understanding these developments is crucial for both current and potential investors....

Continue Reading
Transforming U.S. Textile Waste into Opportunities Abroad

Updated Category News Views 276

Transforming Textile Waste into Global Opportunities A new and insightful report highlights the potential of secondhand clothing exports from the U.S. to tackle the domestic waste crisis while simultaneously promoting economic inclusion in other nations. The Value Chain of Secondhand Clothing Exports Commissioned by Garson and Shaw, this significant report presents an...

Continue Reading
HMNF Financial Achieves New Heights With Record Stock Price

Updated Category News Views 54

HMNF Financial Celebrates New Achievement HMNF Financial has recently attracted attention as its stock price climbed to an impressive $27.25, reaching a new 52-week high. This remarkable milestone demonstrates the company's substantial growth and a strong performance over the past year, highlighted by a staggering 35% rise in stock value. Investor enthusiasm has been...

Continue Reading
Innovative Hackathon Brings AI Payment Solutions to Life

Updated Category News Views 174

Unleashing AI-Driven Payments at the x402 Hackathon Excitement is building as the innovative x402 Hackathon approaches, a premier event dedicated to pushing the boundaries of AI-driven transactions. Hosted by SKALE Network in collaboration with technology giants, this thrilling three-day event encourages developers to reimagine the future of payments on a gas-free...

Continue Reading